Complications in the treatment of CLL with purine analogues
Hematology and Cell Therapy · 1997
DOI: 10.1007/pl00021052 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Hematology and Cell Therapy, 1997. Verfasst von G Juliusson. Beteiligte Einrichtung: Department of Hematology, University Hospital, Linkoping, Sweden. Die Arbeit wurde bisher 6-mal zitiert (Crossref).
Abstract (Originalsprache)
The main complications from treatment of CLL with purine analogues are bone marrow depression resulting in cytopenia, immune suppression leading to infections, particularly opportunistic infections, and immune deregulation with autoimmune hemolytic anemia as the most common feature. These complications usually delay or even prevent further treatment, thus leading to a reduced clinical response. In order to achieve the greatest benefit from purine analogue therapy, it is important to be able to predict the risk of such complications, and to use a treatment strategy with optimal dose intensity, by prophylactic supportive care when required, and by early detection and adequate management of complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology, University Hospital, Linkoping, Sweden.
Zitieren
APA
Juliusson, G. (1997). Complications in the treatment of CLL with purine analogues. Hematology and Cell Therapy. https://doi.org/10.1007/pl00021052
Vancouver
Juliusson G. Complications in the treatment of CLL with purine analogues. Hematology and Cell Therapy. 1997. doi:10.1007/pl00021052
BibTeX
@article{Juliusson1997,
author = {Juliusson, G},
title = {Complications in the treatment of CLL with purine analogues},
journal = {Hematology and Cell Therapy},
year = {1997},
doi = {10.1007/pl00021052}
}
EUVIMED